XML 38 R28.htm IDEA: XBRL DOCUMENT

Segment, Geographical and Other Revenue Information (Tables)

6 Months Ended

Jun. 30, 2021

The following table provides financial information by our reportable business segments along with a reconciliation to consolidated income (loss) before income taxes (in thousands):


	Three months ended June 30, 2021						Three months ended June 30, 2020
	Performance Enzymes		Novel Biotherapeutics		Total		Performance Enzymes		Novel Biotherapeutics		Total
Revenues:
Product revenue	$	14,717	$	—	$	14,717	$	4,504	$	—	$	4,504
Research and development revenue	6,868		3,868		10,736		3,002		7,461		10,463
Total revenues	21,585		3,868		25,453		7,506		7,461		14,967
Costs and operating expenses:
Cost of product revenue	4,318		—		4,318		1,699		—		1,699
Research and development(1)	5,057		7,194		12,251		4,997		5,490		10,487
Selling, general and administrative(1)	3,170		620		3,790		2,375		621		2,996
Total segment costs and operating expenses	12,545		7,814		20,359		9,071		6,111		15,182
Income (loss) from operations	$	9,040	$	(3,946)	5,094		$	(1,565)	$	1,350	(215)
Corporate costs (2)					(8,610)						(5,316)
Unallocated depreciation and amortization					(741)						(506)
Loss before income taxes					$	(4,257)					$	(6,037)


	Six months ended June 30, 2021						Six months ended June 30, 2020
	Performance Enzymes		Novel Biotherapeutics		Total		Performance Enzymes		Novel Biotherapeutics		Total
Revenues:
Product revenue	$	24,943	$	—	$	24,943	$	9,604	$	—	$	9,604
Research and development revenue	10,872		7,670		18,542		8,775		11,258		20,033
Total revenues	35,815		7,670		43,485		18,379		11,258		29,637
Costs and operating expenses:
Cost of product revenue	8,536		—		8,536		4,240		—		4,240
Research and development(1)	11,502		11,799		23,301		10,693		10,415		21,108
Selling, general and administrative(1)	5,988		1,221		7,209		4,720		1,213		5,933
Total segment costs and operating expenses	26,026		13,020		39,046		19,653		11,628		31,281
Income (loss) from operations	$	9,789	$	(5,350)	4,439		$	(1,274)	$	(370)	(1,644)
Corporate costs (2)					(16,335)						(11,042)
Unallocated depreciation and amortization					(1,426)						(998)
Loss before income taxes					$	(13,322)					$	(13,684)

(1) Research and development expenses and selling, general and administrative expenses exclude depreciation and amortization of finance leases.

(2) Corporate costs include unallocated selling, general and administrative expenses, interest income, and other income (expense), net.

The following table provides stock-based compensation expense included in income (loss) from operations (in thousands):


	Three months ended June 30,
	2021								2020
	Performance Enzymes		Novel Biotherapeutics		Corporate cost		Total		Performance Enzymes		Novel Biotherapeutics		Corporate cost		Total
Stock-based compensation	$	1,115	$	257	$	1,472	$	2,844	$	741	$	252	$	946	$	1,939


	Six months ended June 30,
	2021								2020
	Performance Enzymes		Novel Biotherapeutics		Corporate cost		Total		Performance Enzymes		Novel Biotherapeutics		Corporate cost		Total
Stock-based compensation	$	2,109	$	495	$	2,927	$	5,531	$	1,496	$	494	$	2,118	$	4,108

Schedule of Customers that Contributed 10% or More of Total Accounts Receivable

Significant Customers

Customers that each accounted for 10% or more of our total revenues were as follows:


	Percentage of Total Revenues for the
	Three months ended June 30,		Six months ended June 30,
	2021	2020	2021	2020
Customer A	15%	*	10%	*
Customer B	12%	*	*	*
Customer C	12%	*	13%	*
Customer D	*	16%	17%	20%
Customer E	*	38%	10%	27%
Customer F	*	12%	*	11%
Customer G	*	*	*	13%
* Percentage was less than 10%

Customers that each accounted for 10% or more of accounts receivable balances as of the periods presented as follows:


	Percentage of Accounts Receivables as of
	June 30, 2021	December 31, 2020
Customer A	20%	*
Customer H	15%	*
Customer B	15%	*
Customer D	14%	32%
Customer E	10%	*
Customer G	*	25%
Customer F	*	13%
* Percentage was less than 10%

Schedule of Revenues by Geographical Area

Geographic revenues are identified by the location of the customer and consist of the following (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
Revenues
Americas	$	5,844	$	6,906	$	10,773	$	12,131
EMEA	6,169		3,314		12,450		9,285
APAC	13,440		4,747		20,262		8,221
Total revenues	$	25,453	$	14,967	$	43,485	$	29,637

Schedule of Long-Lived Assets by Geographical Area

Identifiable long-lived assets by location was as follows (in thousands):


	June 30, 2021		December 31, 2020
United States	$	31,424	$	31,176

Schedule of Intangible Assets and Goodwill

Identifiable goodwill by reporting unit was as follows (in thousands):


	As of June 30, 2021 and December 31, 2020
	Performance Enzymes		Novel Biotherapeutics		Total
Goodwill	$	2,463	$	778	$	3,241